These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Systemic Adamantiades-Behçet's disease: adverse effects of an otherwise successful therapy with interferon-α-2a]. Karagiannidis I; Zouboulis CC Dtsch Med Wochenschr; 2015 Jan; 140(2):112-3. PubMed ID: 25612283 [TBL] [Abstract][Full Text] [Related]
6. Results of interferon alpha-2a therapy in patients with Behcet's disease. Yalçindağ FN; Uzun A J Ocul Pharmacol Ther; 2012 Aug; 28(4):439-43. PubMed ID: 22455657 [TBL] [Abstract][Full Text] [Related]
7. Potential of Pegylated Interferon Alpha-2a in Behçet Uveitis: A Report of Five Cases. Bielefeld P; Devilliers H; Deschasse C; Saadoun D; Sève P; Muselier A; Creuzot-Garcher C; Besancenot JF; Bron AM Ocul Immunol Inflamm; 2016 Oct; 24(5):599-602. PubMed ID: 25760915 [No Abstract] [Full Text] [Related]
8. Successful use of infliximab in a patient with neuro-Behçet's disease. Abalos-Medina GM; Sánchez-Cano D; Ruiz-Villaverde G; Ruiz-Villaverde R; Quirosa Flores S; Raya Alvarez E Int J Rheum Dis; 2009 Sep; 12(3):264-6. PubMed ID: 20374357 [TBL] [Abstract][Full Text] [Related]
9. Treatment of Adamantiades-Behçet disease with systemic interferon alfa. Zouboulis CC; Orfanos CE Arch Dermatol; 1998 Aug; 134(8):1010-6. PubMed ID: 9722733 [TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and Treatment of Neuro-Behçet: A Clinical Update]. Silva L; Correia J; Santos E Acta Med Port; 2023 Sep; 36(9):588-594. PubMed ID: 37345389 [TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Onal S; Kazokoglu H; Koc A; Akman M; Bavbek T; Direskeneli H; Yavuz S Arch Ophthalmol; 2011 Mar; 129(3):288-94. PubMed ID: 21402983 [TBL] [Abstract][Full Text] [Related]
12. Pseudotumoral Behçet's disease. Alonso S; Riveros-Frutos A; Martínez-Morillo M; Grau-Ferrer L; Carrato C; Olivé A Reumatol Clin; 2016; 12(2):85-90. PubMed ID: 26078022 [TBL] [Abstract][Full Text] [Related]
13. Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients. Lee JH; Lee CS; Lee SC BMC Ophthalmol; 2018 Feb; 18(1):52. PubMed ID: 29463220 [TBL] [Abstract][Full Text] [Related]
14. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease. Park JY; Chung YR; Lee K; Song JH; Lee ES Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144 [TBL] [Abstract][Full Text] [Related]
15. Extensive MRI lesion in brain stem of a neuro-Behcet patient. Kurne A; Arsava EM; Turkmen I; Firat MM; Kansu T Eur J Neurol; 2003 May; 10(3):325-6. PubMed ID: 12752409 [No Abstract] [Full Text] [Related]
16. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Kötter I; Vonthein R; Zierhut M; Eckstein AK; Ness T; Günaydin I; Grimbacher B; Blaschke S; Peter HH; Stübiger N Semin Arthritis Rheum; 2004 Apr; 33(5):311-9. PubMed ID: 15079762 [TBL] [Abstract][Full Text] [Related]
17. [Serial MRI findings in neuro-Behçet disease]. Yamashita Y; Ikeda Y; Tajima H; Okada K; Nakazawa S No Shinkei Geka; 1992 Dec; 20(12):1295-9. PubMed ID: 1484598 [TBL] [Abstract][Full Text] [Related]